TAG:
aco
Clinical Labs and Whole Human Gene Sequencing
By R. Lewis Dark | From the Volume XVII No. 15 – October 25, 2010 Issue
CLINICAL LABORATORY ADMINISTRATORS AND SENIOR EXECUTIVES would be well advised to pay close attention to our lead story about the whole human genome sequence collaboration just announced by the pathology department at Beth Israel Deaconess Medical Center (BIDMC) and GenomeQue…
“Primary-Care Pathology” One Goal at Beth Israel
By Robert Michel | From the Volume XVII No. 15 – October 25, 2010 Issue
CEO SUMMARY: In a pioneering collaboration, the pathology department at Beth Israel Deaconess Medical Center in Boston, Massachusetts, will work with GenomeQuest, Inc., to perform whole genome sequencing of tumor specimens. GenomeQuest will handle sequencing, assembly, and annota…
Hospital-Owned Medical Groups Serving More Patients Per Doc
By Robert Michel | From the Volume XVII No. 14 – October 4, 2010 Issue
IT’S WIDELY KNOWN BY PATHOLOGISTS and laboratory administrators that hospitals and health systems are buying up private medical practices at an accelerating rate. This is a trend that favors hospital laboratory outreach programs, but may not be auspicious for the national laboratories. For this re…
Systems Approach For Pre-Authorization Of Genetic Tests
By Robert Michel | From the Volume XVII No. 14 – October 4, 2010 Issue
CEO Summary: Pre-authorization of expensive genetic and molecular tests is a threat to local clinical laboratories and pathology groups if payers exclude them from provider networks in favor of labs which bid the lowest prices. But one major healthcare corporation believes there …
Payers Move to Pre-Authorize Expensive Genetic Tests
By Robert Michel | From the Volume XVII No. 13 – September 13, 2010 Issue
CEO Summary: Pre-authorization of expensive genetic and molecular tests is fast-becoming a priority for most of the nation’s health insurers. For clinical labs and pathology groups that don’t respond, this trend is a threat. On the other hand, because payers need all the skil…
Specimen Volume Declines Reported By Quest Diagnostics and LabCorp
By Robert Michel | From the Volume XVII No. 11 – August 2, 2010 Issue
IN REPORTING SECOND QUARTER EARNINGS, there was enough difference in the numbers announced by Quest Diagnostics Incorporated and Laboratory Corporation of America to catch the attention of financial analysts. Revenue at LabCorp was up for the quarter while revenue a…
Genetic Testing Genie Is Now Out of the Bottle
By Robert Michel | From the Volume XVII No. 9 – June 21, 2010 Issue
CEO SUMMARY: There’s been an uneasy standoff between companies that want to sell genetic tests directly to consumers over the Internet and both state and federal regulators. But now it appears that the FDA is ready to take off the gloves and assert greater control over genetic …
April 19, 2010 “Intelligence: Late Breaking Lab News”
By Robert Michel | From the Volume XVII No. 6 – April 19, 2010 Issue
Laboratory testing in India continues to attract the attention and investment dollars of western companies. News reports indicate that Apax Partners is negotiating to buy a stake in Metropolis Healthcare of Mumbai, India. Metropolis Healthcare has business activities…
Catholic Health Initiatives Ramps Up Lab Outreach
By Robert Michel | From the Volume XVI No. 17 – December 14, 2009 Issue
CEO SUMMARY: Catholic Health Initiatives (CHI) wants to expand its presence in outpatient and outreach services. It sees hospital laboratory outreach programs as a key component of this strategy. It will use an equity investment in Pathology Associates Medical Laboratories (PAML) as the f…
Physicians in Survey Recognize Lack of Genetic Test Knowledge
By Robert Michel | From the Volume XVI No. 15 – November 02, 2009 Issue
MOST PHYSICIANS BELIEVE they are inadequately informed about pharmacogenomics (PGx) and how to utilize genetic tests. That’s the finding of a survey of 10,303 physicians and reveals an opportunity for pathologists and clinical lab professionals to fill an unmet need. In fact, only 10% of the 10,30…
CURRENT ISSUE

Volume XXXII, No. 6 – April 21, 2025
Now that a federal judge has vacated the FDA’s LDT rule, The Dark Report analyzes the judgement and notes the various steps the FDA could take in response. Also, lab testing at pharmacies is proving to be less successful than was once anticipated.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized